Related Experiment Video
Updated: May 30, 2026
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Ventricular-vascular interaction in heart failure.
Barry A Borlaug1, David A Kass
1Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA. borlaug.barry@mayo.edu
Cardiology Clinics
|August 2, 2011
Summary
Heart failure with preserved ejection fraction (HFpEF) affects nearly half of patients and is linked to increased stiffening of the ventricles and arteries. Understanding this pathophysiology may lead to new HFpEF treatments.
Area of Science:
- Cardiology
- Cardiovascular Physiology
Background:
- Heart failure with preserved ejection fraction (HFpEF) accounts for nearly 50% of heart failure cases.
- HFpEF patients are typically older, female, and hypertensive, exhibiting increased ventricular and arterial stiffness.
Purpose of the Study:
- To discuss the pathophysiology of abnormal ventriculoarterial stiffening in HFpEF.
- To explore the effects of stiffening on cardiac function, hemodynamics, and symptoms.
Main Methods:
- Review of the pathophysiology of ventriculoarterial stiffening.
- Discussion of its impact on cardiovascular parameters.
Main Results:
- Abnormal ventriculoarterial stiffening is a key feature of HFpEF.
- This stiffening impacts ventricular function, cardiovascular hemodynamics, reserve capacity, and symptom presentation.
Conclusions:
- Understanding the abnormal ventricular-arterial interaction is crucial for HFpEF.
- Novel therapeutic strategies targeting this interaction may offer new treatment options for HFpEF.
More Related Videos
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...